FiH Study to Assess Safety and PK of SAD and MAD of ANT3310 Alone and in Combination With Meropenem in Healthy Subjects
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of single and multiple
intravenous ascending doses of ANT3310, a novel, specific, competitive inhibitor of serine
β-lactamases, alone and in combination with meropenem in healthy subjects.